Navigation Links
MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease

ract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RSV disease and is administered by intramuscular injection. Safety and efficacy were established in infants with bronchopulmonary dysplasia (BPD), infants with a history of premature birth (less than or equal to 35 weeks gestation age), and children with hemodynamically significant CHD. Synagis has been used in more than one million children in the U.S. since its introduction in 1998. The first dose of Synagis should be administered prior to commencement of the RSV season. Patients, including those who develop an RSV infection, should continue to receive monthly doses throughout the season.

Very rare cases (<1 per 100,000 patients) of anaphylaxis and rare (<1 per 1,000 patients) hypersensitivity reactions have been reported with Synagis. Cases of anaphylaxis were reported following re-exposure to Synagis and rare severe hypersensitivity reactions occurred on initial exposure or re-exposure. If a severe hypersensitivity reaction occurs, therapy with Synagis should be permanently discontinued. If milder hypersensitivity reaction occurs, caution should be used on re-administration of Synagis.

In clinical trials, the most common adverse events occurring at least 1 percent more frequently in Synagis-treated patients than controls were upper respiratory infection, otitis media, fever and rhinitis. Cyanosis and arrhythmia were seen in children with CHD.

For full prescribing information for Synagis, see the company's website at: www.medimmune.com/products/synagis/index.asp.

About MedImmune, Inc.

MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the ar
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
5. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
6. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
7. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
8. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
9. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:10/22/2014)... -- Moms are ready to live the "measured life" ... kids, according to the results of the BabyCenter® U.S. ... for Moms, the latest installment in BabyCenter,s 21 st ... and parenting web and mobile destination worldwide, conducted the ... say they can,t think of a reason not to ...
(Date:10/22/2014)... A new report by Allied ... Form, End user, Application and Geography) - Size, Share, ... Opportunities, Segmentation and Forecast, 2013 - 2020", considers commercial ... key trends tracked, it is anticipated that the market ... 2020, registering a CAGR of 6.2% from 2014 to ...
(Date:10/22/2014)... -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) ... focused on the development of oral drug delivery ... its Phase IIa clinical trial of ORMD-0801, the ... 1 diabetes. The trial was conducted in ... Food and Drug Administration (FDA) Investigational New Drug ...
Breaking Medicine Technology:BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 2BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 3BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 4Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4
... Inc., a specialty pharmaceutical and diagnostic company, today highlighted ... year ended December 31, 2010. "Prometheus had ... of sales growth," said Joseph M. Limber, President and ... significant progress advancing a number of internal development programs, ...
... 1, 2011 Practice Fusion, the fastest ... the US, today announced Jason Portnoy as the company,s ... cloud-based EMR to physicians; enabling charting, scheduling, e-prescribing and ... of rapid expansion, bringing his deep expertise in scaling ...
Cached Medicine Technology:Prometheus Highlights Record Performance in 2010 2Prometheus Highlights Record Performance in 2010 3Prometheus Highlights Record Performance in 2010 4Prometheus Highlights Record Performance in 2010 5Prometheus Highlights Record Performance in 2010 6Prometheus Highlights Record Performance in 2010 7Prometheus Highlights Record Performance in 2010 8Former PayPal, Palantir Executive Jason Portnoy Joins Practice Fusion as CFO 2Former PayPal, Palantir Executive Jason Portnoy Joins Practice Fusion as CFO 3
(Date:10/22/2014)... For Dr. Iris Hunter, a job is ... extension of her life’s mission. Her extensive experience in the ... of FirstLight HomeCare, make it clear that Hunter’s mission is ... my work makes a difference in the lives of others,” ... after much research, I felt ready to start on this ...
(Date:10/22/2014)... 22, 2014 The Louis ... is dedicated to distribute health information technology innovation ... worldwide announced the development of six key guiding ... when receiving healthcare. These are an expansion of ... “providing care that is respectful of and responsive ...
(Date:10/22/2014)... October 22, 2014 Best Cheap Hosting ... the world. The site has recently announced that iPower ... supplier for people from around the world. , “iPower ... operation today and is providing various kinds of useful ... company insists on offering excellent customer service and a ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Lintelus, Inc., ... Sr. Vice President of Sales, will be speaking on ... Meetings Technology Expo on October 28, at the Holiday ... hosting a booth as well as a Tech Demo ... Meeting can create a more engaging event experience. , ...
(Date:10/22/2014)... Maureen Salamon HealthDay ... Black women undergoing in vitro fertilization (IVF) are only about ... the popular assisted reproduction technique, new research indicates, and the ... In the study, about 31 percent of white patients became ... patients. Analyzing more than 4,000 IVF cycles over two ...
Breaking Medicine News(10 mins):Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3
... medical circles as well as social circles. Every 2nd person ... respite from that is always welcome. ,It was ... resistance syndrome among young obese adults. ,Hyon K. Choi and ... the risk of type 2 diabetes in men in a ...
... activist in Kerala has called for a government probe ... research fraud by reputed publications, The Lancet and the ... medical research community of our country will be questioned ... a government-appointed body investigates the entire scientific activity of ...
... tumor which is found resistant to most of the ... The main causative agents for the development of Malignant ... virus 40 (SV40) is also found to be a ... people with malignant mesothelioma have worked or lived in ...
... you have ever heard about eating sensibly and exercising. The ... fast one day and feast// the next - the way ... revolutionise conventional wisdom about nutrition and dieting, is the result ... National Institute on Ageing here., ,For several years Mattson ...
... on omega-3 fatty acids, has mainly focused on their benefits ... on rats adds //to the mounting evidence of Omega 3 ... have found that diets with a low ratio of omega-6 ... typically brought on by the low levels of oestrogen in ...
... injuries children sustain at home can be of a grave ... that result in deaths. ,Researchers at Cincinnati Children's Hospital Medical ... of the journal Pediatrics// said that preventable injuries sustained at ... year. They have studied the results taken from the National ...
Cached Medicine News:Health News:Research Fraud By Doctor – Probe Demanded 2Health News:Malignant Mesothelioma – A New Genetic Revelation, 2Health News:Malignant Mesothelioma – A New Genetic Revelation, 3Health News:Fasting, Feasting Your Way To Health 2
Inquire...
Inquire...
... the SZX7 is designed for ease of ... from routine preparations to advanced research. The ... ratios in its class as well as ... reproduction of the original specimen in crisp, ...
The modular, high-end stereomicroscope; meets even the most critical demands in research and quality control provides high-contrast images with excellent depth of field and color fidelity...
Medicine Products: